CompanyGraph
What stands out
- Earnings significantly exceed cash generation
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleRevenue is $14.87M, lower than 95% of all stocks globally
- FinancialsAltman Z-Score 11.75: safe zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Earnings significantly exceed cash generation
Financials view
Market Capitalization
12.75BTWD402.35M · vs all stocks (USD)
Trailing P/E
735.45xRevenue (TTM)
471.13MTWD14.87M · vs all stocks (USD)
Profit Margin
4.78%Beta
0.5770xvs all stocks
52-Week Change
-3.58%vs all stocks
Market Capitalization
12.75BTWD402.35M · vs all stocks (USD)
Enterprise Value
12.28BTWD387.66M · vs all stocks (USD)
Trailing P/E
735.45xForward P/E
-28.19xPEG Ratio
-11.66xPrice to Sales (TTM)
27.05xPrice to Book (MRQ)
10.01xEnterprise to Revenue
26.07xEnterprise to EBITDA
-26.96xGross Margin
76.17%Profit Margin
4.78%Operating Margin
-58.18%Return on Assets (TTM)
-17.97%Return on Equity (TTM)
2.00%Revenue (TTM)
471.13MTWD14.87M · vs all stocks (USD)
Revenue per Share (TTM)
3.01TWDUpdated Sep 22, 2026Quarterly Revenue Growth
62.70%Gross Profit (TTM)
366.08MTWD11.56M · vs all stocks (USD)
EBITDA (TTM)
-455.42MTWD-14.38M · vs all stocks (USD)
Net Income (TTM)
22.50MTWD710.18K · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
62.70%Operating Cash Flow (TTM)
-545.15MTWD-17.21M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
8.32MTWD262.79K · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00TWDUpdated Sep 22, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%Revenue
431.27MTWDFY2025 · Dec 31, 2025Cost of Goods Sold
137.06MTWDFY2025 · Dec 31, 2025Gross Profit
294.22MTWDFY2025 · Dec 31, 2025Operating Income
-862.32MTWD-27.22M · vs all stocks (USD)
Pre-tax Income
-858.20MTWDFY2025 · Dec 31, 2025Income Tax Expense
24.95MTWDFY2025 · Dec 31, 2025Net Income
-883.15MTWDFY2025 · Dec 31, 2025EBIT
-852.64MTWDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-784.50MTWDFY2025 · Dec 31, 2025Research & Development
975.13MTWDFY2025 · Dec 31, 2025Selling, General & Administrative
181.40MTWDFY2025 · Dec 31, 2025Non-operating Interest Income
18.17MTWDFY2025 · Dec 31, 2025Non-operating Interest Expense
5.57MTWDFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00TWDFY2025 · Dec 31, 2025Operating Cash Flow
-865.99MTWDFY2025 · Dec 31, 2025Free Cash Flow
-868.96MTWDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
479.52MTWDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-858.20MTWDFY2025 · Dec 31, 2025Stock-based Compensation
33.69MTWDFY2025 · Dec 31, 2025Other Non-cash Items
-12.61MTWDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-8.67MTWDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-20.21MTWDFY2025 · Dec 31, 2025Capital Expenditures
-2.96MTWDFY2025 · Dec 31, 2025Net Intangibles (CF)
-12.54MTWDFY2025 · Dec 31, 2025Purchase of Investments
-220.70MTWDFY2025 · Dec 31, 2025Sale of Investments
75.00MTWDFY2025 · Dec 31, 2025Other Investing Activity
-547.00KTWDFY2025 · Dec 31, 2025Net Investing Cash Flow
-149.21MTWDFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00TWDFY2025 · Dec 31, 2025Long-term Debt Payments
-650.92MTWDFY2025 · Dec 31, 2025Net Short-term Debt Issuance
47.00MTWDFY2025 · Dec 31, 2025Net Financing Cash Flow
-405.69MTWDFY2025 · Dec 31, 2025Shares Outstanding
157.54MSharesUpdated Sep 22, 2026Float Shares
100.30MSharesUpdated Sep 22, 2026% Held by Insiders
52.31%vs all stocks
% Held by Institutions
2.07%vs all stocks
Total Cash (MRQ)
910.92MTWD28.76M · vs all stocks (USD)
Total Cash per Share (MRQ)
5.78TWDUpdated Sep 22, 2026Total Debt (MRQ)
398.33MTWD12.58M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.3129xCurrent Ratio (MRQ)
8.98xBook Value per Share (MRQ)
8.08TWDUpdated Sep 22, 2026Total Assets
1.31BTWD41.37M · vs all stocks (USD)
Total Current Assets
985.71MTWDFY2025 · Dec 31, 2025Total Liabilities
380.78MTWDFY2025 · Dec 31, 2025Total Non-current Assets
324.68MTWDFY2025 · Dec 31, 2025Total Non-current Liabilities
94.47MTWDFY2025 · Dec 31, 2025Total Current Liabilities
286.30MTWDFY2025 · Dec 31, 2025Cash & Cash Equivalents
479.52MTWDFY2025 · Dec 31, 2025Other Short-term Investments
220.70MTWDFY2025 · Dec 31, 2025Accounts Receivable
43.48MTWDFY2025 · Dec 31, 2025Inventory
144.71MTWDFY2025 · Dec 31, 2025Accounts Payable
16.57MTWDFY2025 · Dec 31, 2025Short-term Debt
211.23MTWDFY2025 · Dec 31, 2025Other Current Liabilities
242.00KTWDFY2025 · Dec 31, 2025Long-term Debt
20.50MTWDFY2025 · Dec 31, 2025Common Stock (Book)
1.58BTWDFY2025 · Dec 31, 2025Retained Earnings
-6.69BTWDFY2025 · Dec 31, 2025Total Shareholders' Equity
929.61MTWD29.35M · vs all stocks (USD)
52-Week Low
71.90TWDUpdated Sep 22, 202652-Week High
93.70TWDUpdated Sep 22, 202652-Week Change
-3.58%vs all stocks
Beta
0.5770xvs all stocks
50-Day MA
80.59TWDUpdated Sep 22, 2026200-Day MA
80.37TWDUpdated Sep 22, 2026Avg 10-Day Volume
125.71KSharesUpdated Sep 22, 2026Avg 30-Day Volume
115.86KSharesUpdated Sep 22, 2026Diluted EPS (TTM)
0.1100TWDUpdated Sep 22, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Earnings significantly exceed cash generationSignificant
Net Income (USD, TTM): 710,176.224Operating Cash Flow (USD, TTM): -17,209,935.815
High gross margins eroded by operating costsNotable
Gross Margin: 0.76Profit Margin: 0.05
Financial Health
Altman Z-Score 11.75: safe zoneNotable
Altman Z-Score: 11.75
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Revenue is $14.87M, lower than 95% of all stocks globallySignificant
Revenue (USD): 14,872,977.199Global P5: 33,357,653.812
Companies that share the same coordination system — how they create, deliver, or capture value.
Allergy Therapeutics plc
Tier 1ProductionApproval-Gated PipelineRule
Ars Pharmaceuticals Inc
Tier 1ProductionApproval-Gated PipelineRule
Yantai Zhenghai Bio-Tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Grape King Bio Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Kamada Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Canopus Wisdom MedTech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Relmada Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Editas Medicine Inc.
Tier 1ProductionApproval-Gated PipelineRule
Aarti Drugs Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Opus Genetics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk